Results 41 to 50 of about 32,734 (287)

Heterologous Booster Dose with CORBEVAX following Primary Vaccination with COVISHIELD Enhances Protection against SARS-CoV-2

, 2022
Despite effective vaccination programs, waning immunity in the vaccinated populations and the emergence of variants of concern posed a risk of breakthrough infections.
Venu Simhadri, Apoorva Munigela, Shashidhar Jaggaiahgari, Simhadri, Venu, Mitnala, Sasikala, D, Nageshwar Reddy, Sasikala Mitnala, Gujjarlapudi, Deepika, Deepika Gujjarlapudi, Jaggaiahgari, Shashidhar, Nageshwar Reddy D, Munigela, Apoorva   +11 more
core   +1 more source

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination [PDF]

, 2022
We evaluated the post-vaccination humoral response of three real-world cohorts. Vaccinated subjects primed with ChAdOx1-S and boosted with BNT162b2 mRNA vaccine were compared to homologous dosing (BNT162b2/BNT162b2 and ChAdOx1-S/ChAdOx1-S). Serum samples
Chiara Orlandi, Magnani, Mauro, Marcello Ceccarelli, Eugenio Carlotti, Ceccarelli, Marcello, Daniela Vandini, Carlotti, Eugenio, Orlandi, Chiara, Luca Galluzzi, Gloria Buffi, Barocci, Simone, Anna Casabianca, Galluzzi, Luca, Mauro Magnani, Rocchi, Marco Bruno Luigi, Casabianca, Anna, Aurora Diotallevi, Diotallevi, Aurora, Vandini, Daniela, Simone Barocci, Buffi, Gloria, Marco Bruno Luigi Rocchi   +21 more
core   +1 more source

Immunogenicity and safety of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine: a systematic review

Infectious Diseases of Poverty, 2022
Background Heterologous prime-boost with ChAdOx1 nCoV-19 vector vaccine (ChAd) and a messenger RNA vaccine (BNT or mRNA-1273) has been widely facilitating mass coronavirus disease 2019 (COVID-19) immunisation.
Jingjing Lv, Hui Wu, Junjie Xu, Jiaye Liu   +3 more
doaj   +1 more source

Heterologous prime-boost immunization with ChAdOx1-S and BNT162b2: reactogenicity and immunogenicity in a prospective cohort study

International Journal of Infectious Diseases, 2023
Objectives: Regarding reactogenicity and immunogenicity, heterologous COVID-19 vaccination regimens are considered as an alternative to conventional immunization schemes.
Niko Kohmer, Shivana Stein, Barbara Schenk, Katharina Grikscheit, Melinda Metzler, Holger F. Rabenau, Marek Widera, Eva Herrmann, Sabine Wicker, Sandra Ciesek   +9 more
doaj   +1 more source

Durability of Heterologous and Homologous COVID-19 Vaccine Boosts

JAMA Network Open, 2022
Importance: Antibody responses elicited by current messenger RNA (mRNA) COVID-19 vaccines decline rapidly and require repeated boosting. Objective: To evaluate the immunogenicity and durability of heterologous and homologous prime-boost regimens involving the adenovirus vector vaccine Ad26.COV2.S and the mRNA vaccine BNT162b2.
Tan, C. Sabrina, Collier, Ai-ris Y., Yu, Jingyou, Liu, Jinyan, Chandrashekar, Abishek, McMahan, Katherine, Jacob-Dolan, Catherine, He, Xuan, Roy, Vicky, Hauser, Blake M., Munt, Jennifer E., Mallory, Michael L., Mattocks, Melissa, Powers, John M., Meganck, Rita M., Rowe, Marjorie, Hemond, Rachel, Bondzie, Esther A., Jaegle, Kate H., Baric, Ralph S., Schmidt, Aaron G., Alter, Galit, Le Gars, Mathieu, Sadoff, Jerald, Barouch, Dan H.   +24 more
openaire   +2 more sources

Immune response of heterologous versus homologous prime-boost regimens with adenoviral vectored and mRNA COVID-19 vaccines in immunocompromised patients

Frontiers in Immunology, 2023
Due to rare but major adverse reactions to the AstraZeneca adenoviral ChAdOx1-S-nCoV-19 vaccine (ChAd), German health authorities recommended adults under 60 who received one dose of ChAd, to receive a second dose of the BioNTech mRNA BNT162b2 vaccine ...
Chang Chu, Anne Schönbrunn, Dorothea Fischer, Yvonne Liu, Yvonne Liu, Johann-Georg Hocher, Jutta Weinerth, Kristin Klemm, Kristin Klemm, Volker von Baehr, Bernhard K. Krämer, Bernhard K. Krämer, Bernhard K. Krämer, Bernhard K. Krämer, Saban Elitok, Saban Elitok, Berthold Hocher, Berthold Hocher, Berthold Hocher   +18 more
doaj   +1 more source

Heterologous ChAdOx1 nCoV-19 and mRNA-1273 Vaccination

New England Journal of Medicine, 2021
Heterologous Vaccination with ChAdOx1 nCoV-19 and mRNA-1273 Health care workers who had received a dose of ChAdOx1 nCoV-19 were offered a choice of receiving either ChAdOx1 nCoV-19 or mRNA-1273 9 t...
Johan Normark, Linnea Vikström, Yong-Dae Gwon, Ida-Lisa Persson, Alicia Edin, Tove Björsell, Andy Dernstedt, Wanda Christ, Staffan Tevell, Magnus Evander, Jonas Klingström, Clas Ahlm, Mattias Forsell   +12 more
openaire   +2 more sources

Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection

Emerging Microbes and Infections, 2022
Given emerging evidence of immune escape in the SARS-CoV-2 Omicron viral variant, and its dominance, effectiveness of heterologous and homologous boosting schedules commonly used in low-to-middle income countries needs to be re-evaluated.
Jing Lian Suah, Boon Hwa Tng, Peter Seah Keng Tok, Masliyana Husin, Thevesh Thevananthan, Kalaiarasu M. Peariasamy, Sheamini Sivasampu   +6 more
doaj   +1 more source

Heterologous prime–boost vaccination [PDF]

Current Opinion in Immunology, 2009
An effective vaccine usually requires more than one time immunization in the form of prime-boost. Traditionally the same vaccines are given multiple times as homologous boosts. New findings suggested that prime-boost can be done with different types of vaccines containing the same antigens.
openaire   +2 more sources

Heterologous Immunity Between SARS-CoV-2 and Pathogenic Bacteria

Frontiers in Immunology, 2022
Heterologous immunity, when the memory T cell response elicited by one pathogen recognizes another pathogen, has been offered as a contributing factor for the high variability in coronavirus disease 2019 (COVID-19) severity outcomes.
Peter J. Eggenhuizen, Boaz H. Ng, Janet Chang, Rachel M.Y. Cheong, Anusha Yellapragada, Wey Y. Wong, Yi Tian Ting, Julie A. Monk, Poh-Yi Gan, Poh-Yi Gan, Stephen R. Holdsworth, Stephen R. Holdsworth, Joshua D. Ooi   +12 more
doaj   +1 more source